REGN Potential key support areaPlease pay close attention to this crucial support level. It previously served as a significant resistance level and also represented a period of market equilibrium and concentration.
1REGN trade ideas
REGNabove 1024 heading to 1065
an upward trend in the prices of an industry's stocks or the overall rise in broad market indices, characterized by high investor confidence
REGN possible accumulation at a key levelCM Williams Vix Fix postulates the bottom is forming. REGN did have a pull back to key level and could be accumulating. SRSI levels are in good range. RSI levels are forming to acceptable ranges. Let's see if we get a structure on the key level and positive break out.
Head and Shoulders top The target of the head and shoulders top takes the price down to the long term trend line which will act as a key level of resistance. Some 19% fall from today prices
Breakdown of the 200 EMA will cause the price to drop to the next key level of support and this is about 18-19% lower
REGN should continue rally in bullish daily sequenceREGN favors upside as long as it stays above price trendline as the part of iii started from October-2023 low and expect few more highs before pullback in iv correction.
REGN potential Buy setupReasons for bullish bias:
- Simple DOW theory
- Entry at HH breakout
- No divergence
Here are the recommended trading levels:
Entry Level(CMP): 1000.64
Stop Loss Level: 949.00
Take Profit Level 1: 1052.28
Take Profit Level 2: 1103.92
Take Profit Level 3: Open
regn has been a monster in the making and setting new highsAs we are still in an uptrend, no reversal decision or reversal change in technical analysis. I am interested to see it go up and continue this rise to higher highs, and until we see sudden change in reversal, I will continue to ride the gravy train, up the streets of san fran!!!
Going Long on Regeneron (REGN)Regeneron Pharmaceuticals (REGN) is a stock that has seen an appreciation in its stock price since the beginning of the year. This trading idea focuses on the company's financial performance and its potential for future growth.
Key Metrics:
Gross Profit Ratio: Regeneron's gross profit ratio currently stands at 87.18%. This metric measures the efficiency and effectiveness of the company by dividing its gross profit by its total net sales.
Research and Development (R&D) Expenditures: Regeneron invests $1 billion annually in R&D. This indicates the company's commitment to innovation and the development of new products.
EBITDA: The company's earnings before interest, taxes, depreciation, and amortization (EBITDA) is currently $1.20 billion. This metric provides insights into the company's operating performance.
Debt Ratio: Regeneron's debt ratio, which is the ratio of total debts to total assets, stands at 8.81. This indicates a relatively low level of debt compared to its assets.
Trading Strategy: This trading idea focuses on companies with a moderate investment horizon and a somewhat high risk tolerance. The strategy is to buy the asset, REGN.
Idea Core Logic: This strategy looks for companies that have a high gross profit ratio, indicating efficient and effective performance. It also focuses on companies that invest significantly in R&D, as this suggests a commitment to innovation and future growth. Additionally, companies with a high EBITDA and a low debt ratio are preferred, as they indicate strong financial performance and a healthy balance sheet.
In the case of Regeneron Pharmaceuticals, it meets all these criteria with a gross profit ratio of 87.18%, 1 billion annual R&D expenditures, 1.20 billion EBITDA, and a debt ratio of 8.81. These factors suggest that Regeneron has a strong financial position and potential for future growth, making it an attractive investment opportunity.
Technical Outlook
Regeneron (REGN) bulls are looking to push the stock past a key resistance level at $759.49 as the next upside milestone if bulls maintain their dominance. Technical analysis indicates that a strong downtrend may be forthcoming with short positions being favored when the Commodity Channel Index (CCI) falls below -100.
In today's session, Regeneron continued its 12-day uptrend by gaining 0.29%. The stock climbed to $779.89, showing positive momentum.
In terms of returns, Regeneron has outperformed the Nasdaq by 0.88% so far this year. It currently has a market cap of $83.25 billion.
There were 382,219 shares traded on the day, slightly below the average daily volume of 392,139 shares.
Regeneron recently released its earnings figures, reporting 3.16 billion in revenue and earnings per share of 10.24. Market analysts had forecasted revenues of 3 billion and an EPS of 9.92. For the next earnings report, Regeneron is expected to announce revenues of 3.22 billion and an EPS of 10.8.
Technical analysis indicates a possible new, strong downtrend for Regeneron. The Commodity Channel Index (CCI) indicator is below -100, suggesting that the market price is unusually low and below its moving average. A bullish engulfing candlestick pattern has also appeared on Regeneron's price chart.
$REGN with a bullish outlook following its earnings #StocksThe PEAD projected a bullish outlook for NASDAQ:REGN after a negative under reaction following its earnings release placing the stock in drift D .
#regn buy signal @regn buy position @742.2$
Good financial ratios and good indicators level
@intelligent.investing.144
Nothing yet but wowWhen she goes, OH BABY she'll go.
It's a big flag and $REGN has a lot of positivity behind it. People like the company.
IF POWELL IS GOOD. This may be one of the best reactions.
Just based off of the technical analysis, and what I see on the chart. So pretty.
I don't have the algo on in this one so you can have less influence on an opinion.
Gnotz algo:
REGN: stable bullish trendA price action above 754 supports a bullish trend direction.
The ideal entry price is as close to 750 as possible.
Increase the long exposure for a break above 787.50.
The first target price is set at 807.50.
The second target price is set at 863.00.
Stop-loss 731.00
$REGN with a bullish outlook following its earnings #Stocks The PEAD projected a bullish outlook for $REGN after a positive under over reaction following its earnings release placing the stock in drift A with an expected accuracy of 66.67%.
V can C bullish flag pattern breakout very soon in this Pharma.About:-
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discover, invent, develops, manufactures and commercializes medicines for the treatment of serious diseases. The company commercializes medicines and product candidates for eye diseases, allergic and inflammatory diseases, pain, infectious diseases, and rare diseases.
Now about technical,,,so Regeneron pharmaceuticals in trading in bullish flag pattern since many months and now time has come for breakout. chances are high for breakout as it has done proper consolidation inside the bullish flag pattern...so i am expecting a breakout very soon,,keep an eye on monthly chart once breakout done, could be proper buy for this pharma ticker, and we can expect a rally towards 900+ levels..stop loss could be best support zone for this stock around 739.
Thankyou guy's please don't forget to like and follow me for future updates.
REGN - Channels Down channel and following up channel
I expect a bullish breakout from the current up channel a continuation from the last move up
This expectation is shown with the bars pattern indicator
Daily timeframe
REGN Regeneron Pharmaceuticals Options Ahead of EarningsLooking at the REGN Regeneron Pharmaceuticals options chain ahead of earnings , I would buy the $730 strike price Puts with
2023-2-17 expiration date for about
$16.53 premium.
If the options turn out to be profitable Before the earnings release, I would sell at least 50%.
Looking forward to read your opinion about it.
REGNThe Trend Lines are above. If SPX does not decline, all the stocks can start a rally which I expect cannot exceed the ATH. I expect 2024 will be the bigger rally and this year, I expect fluctuations.
Not an investment reccomendation.
RectanglePrice is above the .236 of the trend up.
Bound in a horizontal trading channel for the time being.
Neutral pattern. Some trade inside the rectangle but it will eventually break to one side or the other.
No recommendation.
EPS (FWD)
42.93
PE (FWD)
17.09
Div Rate (TTM)
-
Short Interest
1.52%
Market Cap
$78.35B
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
🟩 $REGN - Buying againI am buying $REGN again here.
I like the base, the volume signatures are great and it is showing great strength.
The industry is Biotech (and it is in top 30 industries currently in the stock market)
The IBD RS rating is 95
Fund ownership is increasing:
- notable funds owning it are: American Century Focused Dynam, JP Morgan, FIdelity Contrafun, MFS Frowth, Franklin Growth
Buy ideaNice RSI trend line, support from RSI 50 level.
This is usually a strong indication of the trend continuation.
Trade safe
$REGN with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $REGN after a Negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 50%.
REGN // Triangle patternProvided that it closes in the region marked with X, the targets are determined according to Fibonacci, respectively.
REGN Q3 earnings 11/3 @ 6:30amREGN Q3 September 2022 earnings are on 11/3 at 6:30am. Regeneron Pharmaceuticals (REGN) reported Q2 June 2022 earnings of $9.77 per share on revenue of $2.9 billion. The consensus earnings estimate was $8.53 per share on revenue of $2.8 billion. Revenue fell 44.4% compared to the same quarter a year ago. REGN short entry based on its $754 all time high major resistance level which it didn't even break through during the global covid pandemic in 2020. Plus, the nearest support going into earnings on 11/3 is the SMA50 around $663. Any short term pop up is an opportunity to get a higher strike put with a further dated expiry imo.
Q3 September 2022 Consensus:
EPS = $8.77
Revenue = $2.82 B
SMA50 = 663.67
SMA100 = 634.61
SMA150 = 649.19
SMA200 = 641.40
52week high = 754.67
52week low = 538.01
Do your own due diligence, your risk is 100% your responsibility. This is for educational and entertainment purposes only. You win some or you learn some. Consider being charitable with some of your profit to help humankind. Good luck and happy trading friends...
*3x lucky 7s of trading*
7pt Trading compass:
Price action, entry/exit
Volume average/direction
Trend, patterns, momentum
Newsworthy current events
Revenue
Earnings
Balance sheet
7 Common mistakes:
+5% portfolio trades, capital risk management
Beware of analyst's motives
Emotions & Opinions
FOMO : bad timing, the market is ruthless, be shrewd
Lack of planning & discipline
Forgetting restraint
Obdurate repetitive errors, no adaptation
7 Important tools:
Trading View app!, Brokerage UI
Accurate indicators & settings
Wide screen monitor/s
Trading log (pencil & graph paper)
Big, organized desk
Reading books, playing chess
Sorted watch-list
Checkout my indicators:
Fibonacci VIP - volume
Fibonacci MA7 - price
pi RSI - trend momentum
TTC - trend channel
AlertiT - notification
tickerTracker - MFI Oscillator
www.tradingview.com
